JP2019534867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534867A5 JP2019534867A5 JP2019516407A JP2019516407A JP2019534867A5 JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5 JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cannabidiol
- semi
- alkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 4
- 229950011318 cannabidiol Drugs 0.000 claims 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191194 | 2016-09-28 | ||
| EP16191194.6 | 2016-09-28 | ||
| EP17168172.9 | 2017-04-26 | ||
| EP17168172 | 2017-04-26 | ||
| PCT/EP2017/074545 WO2018060282A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534867A JP2019534867A (ja) | 2019-12-05 |
| JP2019534867A5 true JP2019534867A5 (enExample) | 2020-04-09 |
Family
ID=59966776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516407A Pending JP2019534867A (ja) | 2016-09-28 | 2017-09-27 | カンナビノイド受容体結合リガンドを含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190343793A1 (enExample) |
| EP (2) | EP3698785A1 (enExample) |
| JP (1) | JP2019534867A (enExample) |
| KR (1) | KR20190060787A (enExample) |
| CN (1) | CN109803650A (enExample) |
| AU (1) | AU2017333420A1 (enExample) |
| BR (1) | BR112019006194A2 (enExample) |
| CA (1) | CA3036313A1 (enExample) |
| MX (1) | MX2019003544A (enExample) |
| WO (1) | WO2018060282A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| MX360469B (es) | 2012-09-12 | 2018-11-05 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| DE202013012753U1 (de) | 2012-09-12 | 2019-03-04 | Novaliq Gmbh | Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca |
| WO2015011199A1 (en) | 2013-07-23 | 2015-01-29 | Novaliq Gmbh | Stabilized antibody compositions |
| ES2953837T3 (es) | 2015-09-30 | 2023-11-16 | Novaliq Gmbh | 2-perfluorobutil pentano para administración oftálmica |
| CN120884568A (zh) | 2015-09-30 | 2025-11-04 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| AU2017260444B2 (en) | 2016-05-03 | 2019-05-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
| EP3442480B1 (en) | 2016-06-23 | 2019-10-02 | Novaliq GmbH | Topical administration method |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
| US10732712B2 (en) * | 2016-12-27 | 2020-08-04 | Facebook Technologies, Llc | Large scale integration of haptic devices |
| MX388460B (es) | 2017-04-21 | 2025-03-20 | Dermaliq Therapeutics Inc | Composiciones de yodo. |
| CN110650734B (zh) | 2017-05-12 | 2024-11-15 | 诺瓦利克有限责任公司 | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 |
| IL273531B2 (en) | 2017-09-27 | 2024-05-01 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CN118203735A (zh) | 2017-10-04 | 2024-06-18 | 精呼吸股份有限公司 | 电子呼吸致动式直线型液滴输送装置及其使用方法 |
| EP3706843B1 (en) | 2017-11-08 | 2024-06-26 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| JP7665519B2 (ja) * | 2019-02-01 | 2025-04-21 | アルコン インコーポレイティド | 近視を治療するための化合物、組成物及び医薬組成物 |
| WO2020165132A1 (en) | 2019-02-13 | 2020-08-20 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| WO2021044045A1 (en) | 2019-09-06 | 2021-03-11 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| US12576039B2 (en) | 2020-05-18 | 2026-03-17 | Max Biology Co. Ltd. | Lipid-polymer compositions and methods of use |
| US20230363441A1 (en) * | 2020-09-24 | 2023-11-16 | Nicoventures Trading Limited | Formulation |
| JP2023543925A (ja) * | 2020-10-05 | 2023-10-18 | マックス バイオロジー カンパニー リミテッド | カンナビノイド含有組成物及び疾患の処置及び予防のための使用 |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| WO2022169788A1 (en) | 2021-02-03 | 2022-08-11 | Ads Therapeutics Llc | Topical ophthalmological compositions |
| ES3040366T3 (en) | 2021-06-22 | 2025-10-30 | Pneuma Respiratory Inc | Droplet delivery device with push ejection |
| WO2023064477A1 (en) * | 2021-10-13 | 2023-04-20 | Pneuma Respiratory, Inc. | Compositions for delivery of cannabinoids |
| US12161795B2 (en) | 2022-07-18 | 2024-12-10 | Pneuma Respiratory, Inc. | Small step size and high resolution aerosol generation system and method |
| WO2026037894A1 (en) * | 2024-08-15 | 2026-02-19 | Dermaliq Therapeutics, Inc. | Semifluorinated alkane compositions for cleaning the skin |
| WO2026047389A1 (en) * | 2024-08-30 | 2026-03-05 | Vicadia Lda | Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US20080112895A1 (en) | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| WO2010051541A2 (en) | 2008-10-31 | 2010-05-06 | The University Of Mississippi | Compositions containing delta-9-thc-amino acid esters and process of preparation |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| DE202013012753U1 (de) * | 2012-09-12 | 2019-03-04 | Novaliq Gmbh | Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca |
| MX360469B (es) * | 2012-09-12 | 2018-11-05 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| CN106061490A (zh) | 2013-10-09 | 2016-10-26 | 列奥尼达斯·A·约翰逊 | 一种治疗和预防眼部疾病症状或体征的方法及组合物 |
| EP3071193B1 (en) | 2013-11-20 | 2020-01-08 | Panag Pharma Inc. | Compositions and methods for treatment of ocular inflammation and pain |
| MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
-
2017
- 2017-09-27 EP EP20159519.6A patent/EP3698785A1/en not_active Withdrawn
- 2017-09-27 KR KR1020197010976A patent/KR20190060787A/ko not_active Ceased
- 2017-09-27 EP EP17772438.2A patent/EP3518921B1/en active Active
- 2017-09-27 BR BR112019006194A patent/BR112019006194A2/pt not_active IP Right Cessation
- 2017-09-27 JP JP2019516407A patent/JP2019534867A/ja active Pending
- 2017-09-27 CN CN201780058931.9A patent/CN109803650A/zh not_active Withdrawn
- 2017-09-27 CA CA3036313A patent/CA3036313A1/en not_active Withdrawn
- 2017-09-27 AU AU2017333420A patent/AU2017333420A1/en not_active Abandoned
- 2017-09-27 US US16/337,617 patent/US20190343793A1/en not_active Abandoned
- 2017-09-27 WO PCT/EP2017/074545 patent/WO2018060282A1/en not_active Ceased
- 2017-09-27 MX MX2019003544A patent/MX2019003544A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534867A5 (enExample) | ||
| Sambhara et al. | Glaucoma management: relative value and place in therapy of available drug treatments | |
| JP2018529693A5 (enExample) | ||
| AU2017380769B2 (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2015531344A5 (enExample) | ||
| JP2019532931A5 (enExample) | ||
| JP2018531233A5 (enExample) | ||
| JP6824270B2 (ja) | 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子 | |
| BRPI0720355A2 (pt) | Composições oftálmicas para o tratamento de presbiopia, bem como uso das mesmas | |
| IL273531B1 (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
| ES2540151B1 (es) | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico | |
| EP3397255A1 (en) | Compositions for the treatment of presbyopia | |
| JP2009137971A (ja) | 薬剤および薬剤キット | |
| JP7787129B2 (ja) | 眼科組成物 | |
| ES2324130B1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular. | |
| JP2022530471A (ja) | 神経保護のためのカンナビノイドの組成物及び使用方法 | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| US9187468B2 (en) | Topical ocular analgesic agents | |
| WO2016182032A1 (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP3142559B2 (ja) | 止痒剤としての血小板活性化因子拮抗剤の用途 | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| CN121263183A (zh) | 吡美莫司用于治疗患者的特征在于牛津分级量表角膜染色评分为4或5分的干眼症的用途 | |
| KR20130108376A (ko) | 신경 보호 작용을 갖는 약제 배합 |